Cargando…

Prognostic Index for Nonsmall Cell Lung Cancer Based on Immune-Related Genes Expression

Immune system dysregulation is associated with tumor incidence and growth. Here, we established an RNA-based individualized immune signature associated with prognosis for nonsmall cell lung cancer (NSCLC) to guide adjuvant therapy. We downloaded publicly accessible data on RNA expression and clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Ying, Zhu, Hongyu, Shen, Hailin, Liu, Desen, Li, Zhenkai, Shang, Hailong, Du, Hongdi, Wang, Ying, Ye, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526605/ https://www.ncbi.nlm.nih.gov/pubmed/36193311 http://dx.doi.org/10.1155/2022/4779811

Ejemplares similares

Preoperative Prediction Power of Radiomics for Breast Cancer: A Systemic Review and Meta-Analysis
por: Li, Zhenkai, et al.
Publicado: (2022)

Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis
por: Zhou, Ying, et al.
Publicado: (2022)

An Optimal Animal Model of Ischemic Stroke Established by Digital Subtraction Angiography-Guided Autologous Thrombi in Cynomolgus Monkeys
por: Ye, Juan, et al.
Publicado: (2022)

Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images
por: Qian, Jing, et al.
Publicado: (2022)

A new solution model for cardiac medical image segmentation
por: Shang, Hailong, et al.
Publicado: (2020)

Early Stage Finding of an Immune-Enhanced Genetic Subtype of Nonsmall Cell Lung Cancer Related with T-Cell Depletion
por: yang, Ying, et al.
Publicado: (2022)

The Tumor-immune Index is Correlated With the Prognosis of Patients After Curative Resection for Nonsmall Cell Lung Cancer
por: Li, Bobo, et al.
Publicado: (2015)

Effect of mu Agonists on Long-Term Survival and Recurrence in Nonsmall Cell Lung Cancer Patients
por: Wang, Kai, et al.
Publicado: (2015)

Prognostic Impact of Sphingosine Kinase 1 in Nonsmall Cell Lung Cancer
por: Motono, Nozomu, et al.
Publicado: (2021)

Prognostic Biomarkers after Radiotherapy for Nonsmall Cell Lung Cancer Based on Bioinformatics Analysis
por: Li, Kejun, et al.
Publicado: (2022)

The Prognostic Significance of the Histological Types in Patients With Nonsmall Cell Lung Cancer ≤2 cm
por: Hao, Bo, et al.
Publicado: (2021)

Clinical and prognostic significance of Merkel cell polyomavirus in nonsmall cell lung cancer
por: Kim, Gun-Jik, et al.
Publicado: (2017)

Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study
por: Difoum, Francoise, et al.
Publicado: (2022)

Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer
por: Lei, Weijie, et al.
Publicado: (2017)

CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients
por: Kristiansen, G, et al.
Publicado: (2003)

Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer
por: Pelosi, G, et al.
Publicado: (2003)

Bone marrow micrometastasis in nonsmall cell lung cancer: A new prognostic marker?
por: Barbetakis, Nikolaos, et al.
Publicado: (2019)

Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer
por: Zhang, Xiaojun, et al.
Publicado: (2017)

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry
por: Metzenmacher, Martin, et al.
Publicado: (2023)

Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
por: Cadranel, Jacques, et al.
Publicado: (2019)

Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer
por: Ye, Liang, et al.
Publicado: (2017)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

Modern therapies of nonsmall cell lung cancer
por: Jachowski, Andrzej, et al.
Publicado: (2023)

Genetic Variations in Key MicroRNAs are Associated With the Survival of Nonsmall Cell Lung Cancer
por: Wu, Shuangshuang, et al.
Publicado: (2015)

First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
por: Li, Ying, et al.
Publicado: (2014)

Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer
por: Grimminger, Peter P., et al.
Publicado: (2009)

A meta‐analysis: microRNAs’ prognostic function in patients with nonsmall cell lung cancer
por: Yu, Na, et al.
Publicado: (2017)

Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18: A case report
por: Wu, Yimin, et al.
Publicado: (2017)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer
por: Gong, Hua C., et al.
Publicado: (2011)

The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
por: Escobar, Mauricio, et al.
Publicado: (2011)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Thyroid Metastasis from Nonsmall Cell Lung Cancer
por: Namad, Tariq, et al.
Publicado: (2013)

An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer
por: Zhao, Nan, et al.
Publicado: (2015)

Bronchoscopic treatment of inoperable nonsmall cell lung cancer
por: Kniese, Christopher M., et al.
Publicado: (2020)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer
por: Sun, Bochen, et al.
Publicado: (2022)

Liensinine Inhibits Cell Growth and Blocks Autophagic Flux in Nonsmall-Cell Lung Cancer
por: Chang, Minghui, et al.
Publicado: (2022)

Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer
por: Shang, Liqun, et al.
Publicado: (2021)

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs
por: Zhang, Yuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kntj29n5pp7dr5alcanh3eolqu